SCHEMBL3605468

SCHEMBL3605468

COc1cc(C)c(NCc2ccccc2)c(C)c1Cc1ccc(C(C)C)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 1/20 0.39
NPBWR1 P48145 1/20 0.38
MCHR1 Q99705 1/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
MEN1 O00255 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
KMT2A Q03164 1/20 0.38
SLC5A1 P13866 1/20 0.37
SLC5A2 P31639 1/20 0.37
ALDH1A1 P00352 2/20 0.37
HPGD P15428 1/20 0.37
SLC6A2 P23975 1/20 0.37
SLC6A4 P31645 1/20 0.37
SLC6A3 Q01959 1/20 0.37
PTPN1 P18031 1/20 0.36
GAA P10253 1/20 0.36
ATM Q13315 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2C19 P33261 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3604919 0.76 SLC5A2 (0.43) L3MBTL1SLC5A1SLC5A2ALDH1A1GAA
SCHEMBL3594629 0.75 SLC5A1 (0.42) L3MBTL1SLC5A1SLC5A2ALDH1A1GAA
SCHEMBL3598345 0.74 L3MBTL1 (0.43) L3MBTL1MEN1KMT2ASLC5A1SLC5A2
SCHEMBL3595186 0.73 ALDH1A1 (0.43) NPBWR1MCHR1L3MBTL1MEN1NPC1
SCHEMBL3607051 0.72 NR1H4 (0.39) MEN1KMT2ASLC5A1SLC5A2GAA
SCHEMBL3594435 0.71 SLC5A1 (0.42) L3MBTL1SLC5A1SLC5A2ALDH1A1
SCHEMBL3607130 0.70 SLC5A2 (0.36) NPBWR1MCHR1L3MBTL1MEN1NPC1
SCHEMBL533657 0.69 HTT (0.50) HIF1AMEN1KMT2AALDH1A1HPGD
SCHEMBL3593380 0.68 NPBWR1 (0.35) NPBWR1MCHR1L3MBTL1MEN1NPC1
SCHEMBL18183246 0.67 HTT (0.47) HIF1AMEN1KMT2AALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0988036-A1 USE OF DIKETONE TETRACYCLES DERIVATIVES, NOVEL COMPOUNDS OBTAINED AND THEIR APPLICATION IN THERAPY LABORATOIRE INNOTHERA Société Anonyme (FR) 2000-03-29 EP claimed
WO-1998056374-A1 USE OF DIKETONE TETRACYCLES DERIVATIVES, NOVEL COMPOUNDS OBTAINED AND THEIR APPLICATION IN THERAPY LABORATOIRE INNOTHERA, SOCIETE ANONYME (FR) 1998-12-17 WO claimed
US-4599300-A HIGH SPEED AND CONTRADISCOLORATION INHIBITION MITSUBISHI PAPER MILLS, LTD. (JP) 1986-07-08 US claimed
US-4492695-A ANTICONVULSANTS, SEDATIVES, TRANQUILIZERS SYNTHELABO (FR) 1985-01-08 US claimed
WO-2023239892-A1 COMPOUNDS FOR MODULATION OF CD68 AND USES THEREOF ARKUDA THERAPEUTICS (US) 2023-12-14 WO disclosed
EP-3724188-B1 PROGRANULIN MODULATORS AND METHODS OF USING THE SAME ARKUDA THERAPEUTICS (US) 2023-06-07 EP disclosed
US-20210163471-A1 PROGRANULIN MODULATORS AND METHODS OF USING THE SAME ARKUDA THERAPEUTICS 2021-06-03 US disclosed
EP-3724188-A1 PROGRANULIN MODULATORS AND METHODS OF USING THE SAME Arkuda Therapeutics (US) 2020-10-21 EP disclosed
US-20190210978-A1 HIV PROTEASE INHIBITORS GILEAD SCIENCES, INC. (US) 2019-07-11 US disclosed
WO-2019118528-A1 PROGRANULIN MODULATORS AND METHODS OF USING THE SAME ARKUDA THERAPEUTICS (US) 2019-06-20 WO disclosed
EP-1600442-B1 HETEROARYLCARBAMOYLBENZENE DERIVATIVE MSD KK (JP) 2018-01-17 EP disclosed
EP-1637527-B1 CANNABINOID RECEPTOR MODULATOR TAKEDA PHARMACEUTICAL (JP) 2013-04-17 EP disclosed
EP-1071684-B1 IMIDAZO 1,2-a]PYRIDINES AS PERIPHERAL BENZODIAZEPINE RECEPTOR BINDING AGENTS AUSTRALIAN NUCLEAR SCIENCE TEC (AU) 2004-03-17 EP disclosed
US-6379649-B1 USEFUL FOR DIAGNOSIS AND TREATMENT, INCLUDING RADIOTHERAPY, OF DISORDERS THAT ARE CHARACTERIZED BY AN ABNORMAL DENSITY OF PERIPHERAL BENZODIAZEPINE RECEPTORS; NERVE SYSTEM DISPORDERS AUSTRALIAN NUCLEAR SCIENCE & TECHNOLOGY ORGANISATION (AU) 2002-04-30 US disclosed
EP-0988036-A1 USE OF DIKETONE TETRACYCLES DERIVATIVES, NOVEL COMPOUNDS OBTAINED AND THEIR APPLICATION IN THERAPY LABORATOIRE INNOTHERA Société Anonyme (FR) 2000-03-29 EP disclosed
WO-1998056374-A1 USE OF DIKETONE TETRACYCLES DERIVATIVES, NOVEL COMPOUNDS OBTAINED AND THEIR APPLICATION IN THERAPY LABORATOIRE INNOTHERA, SOCIETE ANONYME (FR) 1998-12-17 WO disclosed
EP-0876368-A1 USE OF MONO- OR DIKETONE TETRACYCLIC DERIVATIVES, RESULTING NOVEL COMPOUNDS AND THERAPEUTICAL USE THEREOF LABORATOIRE INNOTHERA Société Anonyme (FR) 1998-11-11 EP disclosed
WO-1997021709-A1 USE OF MONO- OR DIKETONE TETRACYCLIC DERIVATIVES, RESULTING NOVEL COMPOUNDS AND THERAPEUTICAL USE THEREOF LABORATOIRE INNOTHERA (FR) 1997-06-19 WO disclosed
US-4833149-A ANTISECRETORY AGENTS, CALCIUM CHANNEL BLOCKERS ORTHO PHARMACEUTICAL CORPORATION (US) 1989-05-23 US disclosed
US-4727145-A LOCAL ANESTHETICS ORTHO PHARMACEUTICAL CORPORATION (US) 1988-02-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190210978-A1 HIV PROTEASE INHIBITORS PRSS1, SERPINB1, HPN HIF1A 461/4885NPBWR1 2991/4885MCHR1 3799/4885
US-20210163471-A1 PROGRANULIN MODULATORS AND METHODS OF USING THE SAME GRN, PRNP, PSEN1 HIF1A 4522/4885NPBWR1 906/4885MCHR1 1454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.